Ovarian Carcinosarcoma clinical trials

Explore recruiting ovarian carcinosarcoma clinical trials.

Recruiting ovarian carcinosarcoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Ovarian Carcinosarcoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy : ROCSAN study

France, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Ovarian Carcinosarcoma trials by city

Ovarian Carcinosarcoma clinical trials

Recruiting ovarian carcinosarcoma studies right now

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Agnostic Therapy in Rare Solid Tumors

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Study of NTB-928 in R/R OC

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma

Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Also recruiting in Europe

An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy : ROCSAN study

Ovarian Carcinosarcoma trials by city

Other conditions